Skip to main content

Table 2 Summary of cardiac safety with trastuzumab in early breast cancer

From: Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials

TRIAL ARM Baseline LEVF(%) CHF(%) Cardiac death Cardiac follow-up
HERA NIL >= 55 0 1 MUGA scan or echocardiogram at 3–4 wks prior to randomization, and 3, 6, 12, 18, 24, 30, 36, and 60 mos from randomization
  H 1 YEAR   0.6 0  
NSABP-31 AC followed P >= 50 0.8 1 MUGA scan or echocardiogram 3 wks after last AC dose, 6, 9, and 18 mos from randomization, and 3 mos after last trastuzumab dose
  AC followed PH   4.1 0  
NCCTGN9831 AC followed P >= 50 0.3 1 MUGA scan 3 wks after last AC dose, 6 and 9 mos from randomization, and 3 mos after the last trastuzumab dose
  AC followed P and H   2.5 1  
  AC followed PH   3.5 0  
BCIRG006 AC followed D >= 50 0.3 0 After last AC dose, after second docetaxel dose, after end of chemotherapy, and at 3, 12 and 36 mos from randomization. At baseline, at 6 wks, 4.5 mos,13.5 mos, and 37.5 mos from randomization
  AC followed DH   1.6 0  
  DCarbo followed H   0.4 0  
FIN HER NO H >= 50 3 0 MUGA scan or echocardiogram before chemotherapy, after CEF, and 12 and 36 mos after completion of chemotherapy
  H   0 0  
  1. AC, doxorubicin plus cyclophosphamide; BCIRG, Breast Cancer International ;NCCTG, North Central Cancer Treatment Group; NSABP, National Surgical Adjuvant Breast and Bowel Project; P, paclitaxel. MUGA, multigated acquisition;Research Group; Carbo, carboplatin;CHF, congestive heart failure; cum, cumulative incidence; D, docetaxel; H, trastuzumab; HERA, Herceptin® Adjuvant; LVEF, left ventricular ejection fraction;